The role of maternal gut hormones in normal pregnancy: Fasting plasma active glucagon-like peptide 1 level is a negative predictor of fetal abdomen circumference and maternal weight change

European Journal of Endocrinology

Volumn 162, Issue 5, 2010, Pages 897-903

  Valsamakis, Georgios ^a   Margeli, Alexandra ^b   Vitoratos, Nikolaos ^a   Boutsiadis, Anastassios ^a   Sakkas, Evangelos G ^a   Papadimitriou, George ^a   Al Daghri, Nasser M ^c   Botsis, Dimitrios ^a   Kumar, Sudhesh ^c   Papassotiriou, Ioannis ^b   Creatsas, George ^a   Mastorakos, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^c UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; INSULIN; PEPTIDE YY;

ABDOMEN; ADULT; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CAUCASIAN; FEMALE; FETUS GROWTH; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MATERNAL ATTITUDE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; BIRTH WEIGHT; FEMALE; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; ULTRASONOGRAPHY, PRENATAL; WAIST CIRCUMFERENCE;

EID: 77951658373     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0047     Document Type: Article

References (45)

1. Ryan EA & Enns L. Role of gestational hormones in the induction of insulin resistance. Journal of Clinical Endocrinology and Metabolism 1998 67 341-347.
2. Callaway LK, Prins JB, Chang AM & McIntyre HD. The prevalence and impact of overweight and obesity in an Australian obstetric population. Medical Journal of Australia 2006 184 56-59.
3. Catalano PM, Presley L, Minium J & Hauguel-de Mouzon S. Fetuses of obese mothers develop insulin resistance in utero. Diabetes Care 2009 32 1076-1080.
4. Yogev Y & Catalano PM. Pregnancy and obesity. Obstetrics and Gynecology Clinics of North America 2009 36 285-300.
5. Orskou J, Kesmodel U, Henrikson TB & Secker NJ. An increasing proportion of infants weigh more than 4000 grams at birth. Acta Obstetricia et Gynecologica Scandinavica 2001 80 931-936.
6. Ananth CV & Wen SW. Trends in fetal growth among singleton gestations in the United States and Canada, 1985 through 1998. Seminars in Perinatology 2002 26 260-267.
7. Dyer JS, Rosenfeld CR, Rice J, Rice M & Hardin DS. Insulin resistance in hispanic large-for-gestational-age neonates at birth. Journal of Clinical Endocrinology and Metabolism 2007 92 3836-3843.
8. Wajchenberg BL. β-Cell failure in diabetes and preservation by clinical treatment. Endocrine Reviews 2007 28 187-218.
9. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R & Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996 38 916-919.
10. Iltz JL, Baker DE, Setter SM & Campbell KR. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clinical Therapeutics 2006 28 652-665.
11. Monami M, Marchionni N & Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. European Journal of Endocrinology 2009 160 909-917.
12. Drucker DJ & Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 368 1696-1705.
13. Daousi C, Wilding JP, Aditya S, Durham BH, Cleator J, Pinkney JH & Ranganath LR. Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clinical Endocrinology 2009 71 195-201.
14. Chigo E, Broglio F, Arvat E, Maccario M, Papotti M & Muccioli G. Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clinical Endocrinology 2005 62 1-17.
15. Broglio F, Prodam F, Me E, Riganti F, Lucatello B, Granata R, Benso A, Muccioli G & Chigo E. Ghrelin: endocrine, metabolic and cardiovascular actions. Journal of Endocrinological Investigation 2005 28 23-25.
16. Neary MT & Batterham RL. Peptide YY: Food for thought. Physiology and Behavior 2009 97 616-619.
17. Karra E, Chandarana K & Batterham RL. The role of peptide YY in appetite regulation and obesity. Journal of Physiology 2009 587 19-25.
18. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R, Taveras C, Schroppe B & Bessler M. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. International Journal of Obesity 2009 33 786-795.
19. Korner J, Bessler M, Inabnet W, Taveras C & Holst JJ. Exaggerated glucagon-like peptide 1 and blunted glucose dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surgery for Obesity and Related Diseases 2007 3 597-601.
20. Durnin JVGA & Womersly J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72. British Journal of Nutrition 1974 32 77-97.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
22. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, van Haeften T, Renn W & Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000 23 295-301.
23. Cohen O, Epstein GS, Weisz B, Homko CJ & Sivan E. Longitudinal assessment of insulin sensitivity in pregnancy. Validation of the homeostasis model assessment. Clinical Endocrinology 2006 64 640-644.
24. Tomas E & Habener JF. Insulin-like actions of glucagon-like peptide type 1: a dual receptor hypothesis. Trends in Endocrinology and Metabolism 2009 21 59-67.
25. Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF & Andersen DK. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide is a glucoregulatory peptide. Obesity 2008 16 1501-1509.
26. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK & Elahi D. The extrapancreatic effects of glucagon like peptide-1 and related peptides. Journal of Clinical Endocrinology and Metabolism 2009 94 1843-1852.
27. Cypryk K, Vilsboll T, Nadel I, Smyczynska J, Holst JJ & Lewinski A. Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus. Gynecological Endocrinology 2007 23 58-62.
28. Mastorakos G, Valsamakis G, Papatheodorou DC, Barlas I, Margeli A, Boutsiadis A, Kouskouni E, Vitoratos N, Papadimitriou A, Papassotiriou I & Creatsas G. The role of adipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity. Clinical Chemistry 2007 53 1477-1483.
29. Woods YL, Petrie JR & Sutherland C. Dissecting insulin signaling pathways: individualised therapeutic targets for diagnosis and treatment of insulin resistant states. Endocrine, Metabolic & Immune Disorders Drug Targets 2009 9 187-198.
30. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M & Bode B. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52 week, phase III, double blind, parallel treatment trial. Lancet 2009 373 473-481.
31. Egan JM & Margolskee RF. Taste cells of the gut and gastrointestinal chemosensation. Molecular Interventions 2008 8 78-81.
32. Kyriakakou M, Malamitsi-Puchner A, Militsi H, Boutsikou T, Margeli A, Hassiakos D, Kanaka-Gantenbein C, Papassotiriou I & Mastorakos G. Leptin and adiponectin concentrations in intrauterine growth restricted and appropriate for gestational age foetuses, neonates and their mothers. European Journal of Endocrinology 2008 158 343-348. (Pubitemid 351404998)
33. Hay WW Jr. Metabolic interrelationships of placenta and fetus. Placenta 1995 16 19-30.
34. Regnault TRH, De Vrijer B & Battaglia FC. Transport and metabolism of amino acids in placenta. Endocrine 2002 19 23-41. (Pubitemid 36106250)
35. Herrera E. Lipid metabolism in pregnancy and its consequences in the fetus and newborn. Endocrine 2002 19 43-55. (Pubitemid 36106251)
36. Higgins JR, Quinlivan EP, McPartlin J, Scott JM, Weir DG & Darling MR. The relationship between increased folate catabolism and the increased requirement for folate in pregnancy. British Journal of Obstetrics and Gynaecology 2001 107 1149-1154.
37. Lee BE, Hong YC, Lee KH, Kim YJ, Kim WK, Chang NS, Park EA, Park HS & Han HJ. Influence of maternal serum levels of vitamins C and E during the second trimester on birth weight and length. European Journal of Clinical Nutrition 2004 58 1365-1371. (Pubitemid 39377918)
38. Ghebremeskel K, Burns L, Burden TJ, Harbige L, Costeloe K, Powell JJ & Crawford M. Vitamin A and related essential nutrients in cord blood: relationships with anthropometric measurements at birth. Early Human Development 1994 39 177-188.
39. Ritchie LD, Fung EB, Halloran BP, Turnlund JR, Van Loan MD, Cann CE & King JC. A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. American Journal of Clinical Nutrition 1998 67 693-696.
40. Ding X, Saxena NK, Lin S, Gupta NA & Anania FA. Exendin-4 a glucagon-like peptide-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006 43 173-181. (Pubitemid 43733604)
41. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O & Odaka H. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitasone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. European Journal of Pharmacology 2009 602 448-454.
42. Sodowski K, Zwirska-Korczala K, Kuka D, Kukla M, Budziszewska P, Czuba B, Wloch A, CnotaW, BielanskiW, Brzozowski T, Rehfeld JF, Zdun R & Konturec PC. Basal and postprandial gut peptides affecting food intake in lean and obese pregnant women. Journal of Physiology and Pharmacology 2007 58 37-52. (Pubitemid 350022257)
43. Tham E, Liu J, Thompson D, Gaylinn BD, Bogarin R, Haim A, Thorner MO & Chanoine JP. Acylated ghrelin concentrations are markedly decreased during pregnancy in mothers with and without gestational diabetes: relationship with cholinesterase. American Journal of Physiology. Endocrinology and Metabolism 2009 296 1093-1100.
44. Saad MF, Bernaba B, Hwu CM, Jinagouda S, Fahmi S, Kogosov E & Boyadjian R. Insulin regulates plasma ghrelin concentration. Journal of Clinical Endocrinology and Metabolism 2002 87 3997-4000. (Pubitemid 34879561)
45. Orio F Jr, Lucidi P, Palomba S, Tauchmanova L, Cascella T, Russo T, Zullo F, Colao A, Lombardi G & De Feo P. Circulating ghrelin concentrations in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 942-945. (Pubitemid 36207846)